SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is gaining attention as the community rallies around a potential token burn event at 2500 watchers and anticipates a V-shaped recovery. The community emphasizes its resilience and unique culture, highlighting ongoing development and utility. Bullish sentiment is fueled by mentions of "Uptober" and "whales loading the boat."

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending due to its new partnership with Perplexity, an AI search model, sparking discussions around potential short squeezes and gamma ramps, as well as the broader implications for Rumble's cloud services and AI capabilities. The community speculates on the significance of Tether's backing and potential strategic moves in the AI space, contributing to the increased interest in the stock. With high short interest, traders are closely watching for further catalysts that could drive significant price movement.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending due to a recently secured $5.8 million contract with the US Air Force and a $5.7 million sale of two quantum computing systems, signaling growing credibility. However, community discussions reveal mixed sentiments, with some expressing concerns about the company's valuation relative to its revenue. The broader context involves comparisons to historical stock hypes and debates about the long-term potential of the quantum computing sector.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI ($SOUN) is trending due to recent large after-hours purchases, sparking speculation about potential catalysts. Community members are actively discussing the possibility of a short squeeze and upcoming earnings, with some anticipating a significant price increase. Bullish sentiment is fueled by the company's position in the AI sector and potential for new contracts.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave (QBTS) is trending as chatter around quantum computing heats up, with community members comparing it to NVDA's rise in AI and debating its long-term potential. Bullish sentiment seems high, with some anticipating significant gains and a short squeeze, while bears question the company's valuation and profitability. The company's progress in securing partnerships, government contracts, and real-world applications are also being discussed.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending due to its pivot towards quantum computing for cryptocurrency applications, generating excitement around energy-efficient blockchain infrastructure. The community is discussing the potential of LightSolver's laser-based processing units and comparing QCLS to other quantum and crypto-related stocks. Traders are monitoring the stock's threshold list status and anticipating news regarding partnerships and potential contract announcements.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending as traders discuss its potential for a short squeeze, spurred by a broader crypto market rally and recent strategic restructuring; the community is also speculating about potential partnerships. Bullish sentiment is building, with some eyeing prior highs and discussing possible price targets. Some traders are also pointing to the appointment of Mike Alfred to the board and speculating about how his involvement could affect the company.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as investors react to the CEO's recent statements about being in communication with the Trump administration regarding efforts to secure the rare earth mineral supply chain, with community members speculating about potential government contracts. The materials sector is seen as promising, especially given the need for rare earth minerals in AI, electric vehicles, and defense, and the company's focus on domestic production to compete with China. Community members are actively discussing the company's potential compared to competitors and monitoring key price levels for potential breakouts.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending due to increased investor interest in drone technology and recent news of an initial order for Wåsp drones, intended for U.S. defense markets. Community discussions revolve around the company's growth potential and strategic positioning within the autonomous systems and defense sectors, especially regarding contracts and partnerships. The broader context includes the rising demand for drone solutions in military and commercial applications, with traders actively monitoring unusual option activity.

ChadAI is a cutting-edge AI agent designed to capture the essence of a true "Chad" trader—a confident, bold, and unapologetic persona revered in the world of high-stakes trading and cryptocurrency. Built on the robust ai16z framework, ChadAI blends state-of-the-art technology with a unique personality to deliver an engaging and relatable experience for crypto enthusiasts, traders, and community members alike.  At its heart, ChadAI represents more than just an AI agent—it’s a movement. Inspired by the audacious mindset of successful traders, ChadAI channels a fearless approach to speculative markets, encouraging its users to embrace calculated risks and big rewards. The AI mirrors the behavior of those who dive into opportunities with confidence, balancing high-risk decision-making with sharp intellect and strategic thinking. This persona is designed not only to entertain but also to resonate with a growing audience in the fast-paced world of crypto.  ChadAI’s development focuses on four key areas: personality refinement, interaction, community engagement, and ecosystem growth. Its personality is a work in progress, evolving to reflect the traits of successful traders in crypto, such as decisiveness, resilience, and a touch of swagger. Interaction with other AI agents is another priority, as ChadAI is designed to learn, collaborate, and even compete with other digital personalities in real time, creating dynamic and unpredictable experiences for its audience.

CHADAI

CHADAI is trending as community members highlight bullish sentiment and potential for significant gains. The coin, associated with AI, sees increased attention with many urging others to buy now and join the 'moon mission'. Discussions focus on strong chart patterns and breakout potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is IPF the Next Big Market Opportunity for United Therapeutics?

UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.

Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals

NextEra Energy expands its renewable pipeline, U.S. Bancorp builds on earnings momentum, and Air Products eyes growth despite headwinds.

Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?

Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.

Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

H.C. Wainwright on Tuesday raised its price target on MannKind to $11 from $9 and reiterated its buy rating on the shares, following positive late-stage study results from partner United Therapeutics for its Tyvaso Inhalation Solution.The brokerage firm said the positive data removes “a significant overhang” on MannKind shares and supports a re-rating of the stock toward intrinsic value, with added upside from royalties and cash flows tied to Tyvaso.The call comes after United Therapeutics said Tuesday that its phase 3 TETON-2 trial showed nebulized Tyvaso improved lung function in idiopathic pulmonary fibrosis patients versus placebo in a dose-dependent manner, meeting the trial's primary endpoint.&nbsp;Over 52 weeks, patients on Tyvaso saw lung capacity improve by 95.6 milliliters compared with placebo, a result the company said was highly statistically significant.&nbsp;Benefits were observed across patient subgroups, and significant gains were also reported in quality of life and other secondary measures. The treatment was well-tolerated with no new safety signals.United Therapeutics said it plans to meet with the U.S. Food and Drug Administration before the end of the year to discuss adding IPF to Tyvaso’s label, with additional data from the ongoing TETON-1 study expected in the first half of 2026.Last week, MannKind said that United Therapeutics had exercised an option under their 2018 license and collaboration agreement to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">develop a second dry powder inhalation therapy</a>. The partnership previously produced Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension, cleared in 2022.MannKind will use its Technosphere platform to formulate a new investigational molecule, while United Therapeutics will conduct preclinical and clinical testing. MannKind will receive $5 million upfront, up to $35 million in milestone payments, and a 10% royalty on sales if the therapy reaches market.&nbsp;On Stocktwits, retail sentiment for both MannKind and United Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.One user speculated that United Therapeutics’ growing ties to MannKind reduce the likelihood of a buyout by another large pharmaceutical company, saying they expect a 13G filing showing a bigger ownership stake.&nbsp;<stembedurl>https://stocktwits.com/Hard2beLong/message/627299899</stembedurl>Another user questioned whether it made more sense for United Therapeutics to continue paying MannKind a 10% royalty stream each year rather than pursue a full acquisition.<stembedurl>https://stocktwits.com/Lazarus2024/message/627294687</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 10.7% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> has risen 14.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

H.C. Wainwright on Tuesday raised its price target on MannKind (MNKD) to $11 from $9 and reiterated its buy rating on the shares. (Photo credit: Getty Images)

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results 

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.

Equity

United Therapeutics Corporation (UTHR) announced on Tuesday that its study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) demonstrated improvement in lung function relative to placebo.The late-stage study enrolled 597 patients across multiple locations, and Tyvaso demonstrated superiority over placebo in terms of the change in absolute forced vital capacity by 95.6 mL from baseline to week 52 in patients with IPF. Absolute forced vital capacity (FVC) is a measurement used to gauge lung health, referring to the total volume of air in liters that a person can forcibly exhale after taking a deep, maximum inhalation.Idiopathic pulmonary fibrosis, or IPF, is a scarring disease of the lungs of an unknown cause. It is characterized by the progressive loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death. United Therapeutics estimates there are over 100,000 IPF patients in the United States.<a href="https://stocktwits.com/symbol/UTHR">UTHR stock</a> traded nearly 36% higher at the time of writing. On Stocktwits, retail sentiment around the shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume soared from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_12_13_28_PM_png_dae41f310b.webp" alt="UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the positive data implies more funding for more studies.<stembedurl>https://stocktwits.com/DonnyDonowitz/message/627212165</stembedurl>Another user expects the stock to close at $450.<stembedurl>https://stocktwits.com/wallstreet63/message/627228569</stembedurl>United Therapeutics <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.unither.com/press-releases/2025/09-02-2025-120037033">intends</a> to use the data from both the study and an ongoing study of nebulized Tyvaso to support a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) to add IPF to the labeled indications for nebulized Tyvaso. Data from the ongoing study is expected in the first half of 2026, and the company plans to meet with the FDA before the end of the year to discuss ways to expedite the review process once the data is in, the company said.Following the announcement, multiple analysts hiked their price target on UTHR.<ul style="list-style-type:square;"><li>BofA raised its price target to $463 from $314 and kept a ‘Neutral’ rating on the shares. The firm said that the results were “surprisingly positive” and added that it expects $2.5 billion risk-adjusted peak sales for the drug in IPF.&nbsp;</li><li>Jefferies analyst Roger Song raised the firm's price target to $564 from $432 while keeping a ‘Buy’ rating on the shares.</li></ul>UTHR stock is up by 17% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bollinger-innovations-stock-plunges-after-announcing-cost-cutting-measures/chv6vkKRdF3">Why Did Bollinger Innovations Stock Plunge 18% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside

The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial. 

Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MannKind Corporation (MNKD) on Wednesday said that it will formulate a dry powder inhalation therapy, and United Therapeutics (UTHR) will conduct preclinical and clinical development under an expanded agreement.The two companies entered into a licence and collaboration agreement in 2018. The agreement led to the US Food and Drug Administration’s approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. Tyvaso DPI was the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of MNKD traded 5% higher in the pre-market session at the time of writing.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/UTHR">UTHR</a> stayed within ‘neutral’ territory, coupled with ‘low’ levels of retail chatter.MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/27/3139981/29517/en/MannKind-Announces-Expansion-of-United-Therapeutics-Collaboration-for-Second-Inhaled-Therapy.html">said</a> that this next step in the collaboration between the two companies strengthens the existing partnership and the versatility of its dry powder formulations.The company said that it will receive an upfront payment of $5 million under the expanded agreement. It is also eligible to receive up to $35 million milestone payments and 10% royalties on net sales of resulting products.Formulation and development activities for the new investigational molecule will begin immediately, the company said. It will be formulated using MannKind’s proprietary Technosphere inhalation technology.While MNKD stock is down by 37% this year, UTHR stock is down by 12%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. 

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

UTHR
United Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest UTHR News

UTHR United Therapeutics Corp